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Recent developments in the study of epithelial ovarian cancer have called into question the
traditional views regarding the site of tumor initiation. Histopathologic studies and genomic
analyses suggest that extra-ovarian sites, like the fallopian tube, may harbor the coveted
cell of origin and could therefore contribute significantly to the development of high-grade
serous ovarian carcinoma (HG-SOC). Our ability to validate these emerging genomic and
pathologic observations and characterize the early transformation events of HG-SOC hinges
on the development of novel model systems. Currently, there are only a handful of new
model systems that are addressing these concerns. This review will chronicle the con-
vergent evolution of these ovarian cancer model systems in the context of the changing
pathologic and genomic understanding of HG-SOC.
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INTRODUCTION
In 2013, the American Cancer Society estimates that 22,240 women
will receive a new diagnosis of ovarian cancer and that 14,030
women will die from this disease, making ovarian cancer the most
lethal gynecological malignancy in the United States (1). Of these
newly diagnosed cases, 80% of the serous ovarian carcinomas are
diagnosed at late stage, for which the 5-year survival rate is only 9–
35% (2). Despite advancements in technology, this poor survival
rate has been consistent over the last 30 years, an indictment of the
complexity of this disease. In order to combat this clinical chal-
lenge, it is imperative to generate robust early detection methods
and novel treatment options.
Many of the characteristics confounding the study of ovar-
ian cancer arise from the disease’s heterogeneity. Ovarian tumors
can arise from three different cell types; epithelial, germ, and
sex cord stromal cells, with epithelial accounting for approx-
imately 90% of all ovarian cancers (1). Epithelial tumors are
further grouped into different tumor types: Type I and Type II.
Type I tumors include low-grade serous carcinoma, low-grade
endometrioid carcinoma, mucinous carcinoma, and a subset of
clear cell carcinomas, which develop in a stepwise fashion from
well-recognized precursors, in most cases, borderline tumors (3–
5) (Figure 1). These tumors are slow to develop and are generally
confined to the ovary (6). Type I tumors are also genetically stable,
with each histologic subtype corresponding to a distinct genetic
profile (4–6). In contrast, Type II tumors encompass high-grade
serous carcinoma, undifferentiated carcinoma, malignant mixed
mesodermal tumor (carcinosarcoma), and some clear cell car-
cinomas (3) (Figure 1). High-grade serous carcinomas are the
most common Type II tumor. These tumors progress rapidly, har-
bor TP53 mutations, and exhibit widespread DNA copy number
alterations (3–7).
This new appreciation of tumor diversity and the rapid devel-
opment of genomic technologies have helped redefine “ovarian
cancer.”As the field grapples with these emerging concepts, exper-
imental model systems will likely play a vital role in defining new
opportunities for early detection and therapeutic intervention.
This review will highlight the recent advancements in ovarian can-
cer genetics and pathology, and explore the past and present model
systems employed to study high-grade serous ovarian carcinoma
(HG-SOC).
GENETICS
Until recently, neoplastic transformation was thought to be dri-
ven by the sequential acquisition of mutations in critical genes.
For many epithelial cancers, including Type I ovarian cancer, this
is true. The most prominent mutations present in Type I tumors
include alterations to KRAS, BRAF, PTEN,CTNNB1, andTGFBR2
(3, 6, 8). However, besides mutations in theTP53 tumor suppressor
gene and the BRCA1 or BRCA2 genes, very few recurrent somatic
mutations have been associated with the more aggressive Type II
tumors (6). This inability to systematically characterize Type II
tumors was addressed by the National Cancer Institute (NCI) and
the National Human Genome Research Institute (NHGRI) in the
creation of The Cancer Genome Atlas (TCGA). In the TCGA’s
pilot study of HG-SOC, microarray analyses and new sequencing
technology were used to publish the largest and most comprehen-
sive genetic analysis of HG-SOC. The study encompassed mRNA
expression, microRNA expression, DNA copy number, and DNA
promoter region methylation for 489 HG-SOC and whole exome
DNA sequence information for 316 of these samples (7).
Results from the initial TCGA study characterized HG-SOC
as having TP53 mutations in nearly 100% of tumors and identi-
fied low prevalence but statistically significant recurrent somatic
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FIGURE 1 |The major histologic subtypes of ovarian cancer fall
into two subclassifications. Type I tumors are low-grade, slow
growing carcinomas that typically arise from well recognized
precursors lesions (borderline tumors) that themselves develop from
the ovarian surface epithelium, inclusion cysts, or endometriosis. In
contrast, Type II tumors are high-grade and rapidly growing carcinomas.
Typically, they have spread well beyond the ovary at the time of
diagnosis.
mutations in nine additional genes including NF1, BRCA1,
BRCA2, RB1, andCDK12 (7). TCGA also described 113 DNA copy
number alterations and implicated 168 genes involved in promoter
methylation events (7). Considering the widespread DNA copy
number aberrations observed across HG-SOC, it has been sug-
gested that disruption of DNA repair pathways followed by chro-
mosome instability is a viable model for the early progression of
HG-SOC (9, 10). The TCGA provides an expanding database that
is useful in identify high impact genes. However,because the TCGA
studies the advanced state of HG-SOC, determining whether these
genes are important to transformation, or instead are related
to tumor maintenance, immune evasion, anti-apoptosis, and/or
chemoresistance, requires further investigation.
PATHOGENESIS
Historically, ovarian cancer was believed to originate from the
ovarian surface epithelium (OSE), where ovulation, follicular rup-
ture, oocyte release, cytokine exposure, and reactive oxygen species
introduce DNA damage into the ovarian epithelial layer (11, 12).
Proposed back in 1971, the Fathalla “incessant ovulation” hypoth-
esis (13) suggests that over a woman’s lifespan, the accrual of
DNA damage and the development of cortical inclusion cysts
(CICs) results in Mullerian metaplasia of the coelomic epithelium
followed by neoplastic transformation (14, 15). This hypothesis
attempts to explain the presentation of coexisting serous and non-
serous tumor subtypes within ovarian tumors and incorporates
the epidemiological data linking ovulatory activity with risk of
ovarian cancer (16). However, while precursor lesions have been
identified in the OSE that are linked to Type I tumors (17), repro-
ducible pre-malignant lesions have been difficult to identify in the
OSE for the high-grade Type II tumors.
A more recent analysis compares the major subtypes of ovarian
carcinomas to tumors arising in the fallopian tube, endometrium,
and endocervix. Evidence suggests that benign structures derived
from these anatomic locations may serve as sites of origin for
all tumors that have traditionally been regarded as of primary
ovarian origin. Such epithelial structures, which include endos-
alpingiosis, endometriosis, and endocervicosis, represent non-
neoplastic counterparts of serous, endometrioid/clear cell, and
mucinous ovarian carcinomas, respectively, and are referred to
as extra-uterine Müllerian epithelium (EUME) (15).
The most significant studies supporting the concept of EUME
are those implicating the fallopian tube fimbria as the site of ori-
gin for high-grade serous carcinomas. Early studies of fallopian
tube carcinomas noted TP53 and interleukin 6 (IL-6) mutations
(18, 19). However, a link to ovarian cancer was not proposed until
pathologists systematically analyzed fallopian tubes from women
carrying mutations in the BRCA1 tumor suppressor gene. These
studies identified preneoplastic lesions localized to the tubal fim-
bria (20–22), where they displayed secretory cell histology, DNA
damage, mutations in TP53, and stable p53 protein expression
(20, 23). This evidence suggests that HG-SOC tumor progres-
sion within the fallopian tube fimbria begins withTP53 mutations
(p53 signatures), evolves to serous tubal intraepithelial carcinoma
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FIGURE 2 | Early tumor progression within the fallopian tube and the
resultant genetic profile of HG-SOC. This illustration depicts the recently
identified precursor lesions of HG-SOC that are present in the fallopian tube.
Mutations in theTP53 tumor suppressor gene are a very early event in the
pathogenesis of HG-SOC, occurring exclusively in benign-appearing secretory
cells. These preneoplastic lesions are referred to as ‘p53 signatures’.
Acquisition of a neoplastic phenotype and proliferative capacity results in the
development of serous tubal intraepithelial carcinoma (STIC). Breaching of the
basement membrane and localized dissemination to the ovary and/or
peritoneal cavity heralds the development of invasive HG-SOC and the
associated clinical scenario. HG-SOCs that involve the ovary or peritoneum
are characterized by mutations inTP53 (and BRCA1 in familial cases) and
display a complex genomic terrain with widespread copy number alterations
throughout the genome.
(STIC), and eventually transforms and metastasizes to the ovary
presenting as HG-SOC (20, 24) (Figure 2).
EXPERIMENTAL MODELS OF HG-SOC
Experimental models systems in ovarian cancer biology have
evolved significantly over the past 10–15 years. Today there exist
a number of useful models that continue to advance transla-
tional research in ovarian cancer (Figure 3). It is beyond the
scope of this mini-review to address all available experimental
models. However, in order to demonstrate the utility and evolu-
tion of these research tools, a select few of these models will be
discussed.
XENOGRAFTS
Xenograft models are possibly the most utilized experimental
platform in the field of cancer research. Early developments of
this model were reported in the late 1960s when Rygaard et al.
found that mice suffering from recessive thymic aplasia could grow
mammary and colon xenografted carcinomas (25). This effec-
tively spawned the immunocompromised rodent model, which,
due to its ease of application and histological insights, pro-
vided an extensive tool to study ovarian cancer tumorigenesis,
chemotherapeutics, and biomarkers (26–29).
Despite its utility, questions still remain whether compromising
the rodent immune system affects the tumor microenvironment.
Various studies have shown that cell lines implanted in immune-
compromised mice can lose their histological fidelity (30–33).
Likewise, monitoring disease formation and progress is also com-
plicated with immune-compromised mice,as disease and infection
rates increase when mice are handled outside their protective
environment. To combat this, a small number of syngeneic mod-
els have been developed (34, 35). However, this digression from
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FIGURE 3 | Model systems from primary human tissues. An array
of experimental model systems spanning in vitro and in vivo
approaches have been developed to study ovarian cancer. The models
include platforms to interrogate the biology of cancer cells as well as
for the study of benign epithelium. The expansion beyond traditional
two-dimensional (2D) cell culture into 3D and organoid cultures has
yielded important insights into the biology of this disease, as has the
development of unique animal models. Development of these
models is critical as our understanding of this cancer continues to
evolve.
human disease presents its own complications when translating
experimental results into the clinical setting.
The location of tumor formation and its histologic fidelity to
the human disease is also a concern when using xenograft models.
The bursal membrane in rodents encapsulates the ovary and cre-
ates a unique microenvironment unlike the human equivalent. By
acting as a barrier to the peritoneal cavity, the bursal membrane
could hinder the development of these tumors (36). In addition,
the anatomy of the murine reproductive system departs from that
of humans and contains a bicornuate uterus with the fallopian
tubes embedded in the aforementioned bursa. Furthermore, the
intermittent ovulatory cycle of the mouse corresponds to its rare
development of spontaneous ovarian carcinomas (37).
Even with these limitations, xenograft models are still impor-
tant in translational research and have broad utility. All drug
treatments must show promise in animal studies prior to investiga-
tion in human clinical trials. In addition, because a high priority
has been placed on characterizing the early events of HG-SOC,
xenograft models can be effectively paired with in vitro trans-
formation studies to characterize preneoplastic and metastatic
events (Figure 3). Karst et al. demonstrated this by confirming the
transformative and metastatic potential of fallopian tube secre-
tory epithelial cells (FT-SECs) in nude mice (38). Considering this
versatility and practicality, the future use of xenograft models in
ovarian cancer research is a certainty.
CELL CULTURE MODELS
OSE models
Prior to 1981, the isolation of untransformed primary ovarian tis-
sue within the laboratory was unprecedented, making it difficult to
discern molecular events related to transformation. This changed
in 1981 when Adams and Auersperg isolated and transformed rat
OSE (ROSE) cells with the Kirsten murine sarcoma virus (Ki-
MSV) (39). The impact of this initial study led to the optimization
of cell culture techniques (40, 41) and prompted investigators to
start creating a vast cell bank for future studies.
Investigators took advantage of this new technology in the
early 1990s when a series of studies simulated incessant ovulation
through repeated in vitro passaging of rodent OSE cells. Investi-
gators found that primary ROSE and mouse OSE (MOSE) cells
that had undergone serial propagation exhibited increased prolif-
erative and tumorigenic properties (35, 42, 43). Further analyses
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indicated that these transformed cell lines displayed similar pro-
liferative and genomic patterns observed in human tumors. This
was the first comparative analysis between a transformed cell line
and its primary parental line and provided supporting evidence
for the Fathalla Hypothesis.
While these studies were limited to rodent OSE cells, stud-
ies involving isolated human OSE (HOSE) cells were also being
attempted (44–46). However, unlike rodent OSE cells, HOSE cells
have a limited growth potential in vitro and require genetic per-
turbations to increase cellular lifespan (Figure 3). In order to
achieve immortalization, two important questions require con-
stant attention; what are the pathways critical to immortalization
and how can one alter those pathways without disrupting the nor-
mal function of the cell? Initially, these genetic perturbations were
achieved via retroviral transduction of either the human papilloma
virus E6/E7 oncogenes or the simian virus 40 T antigen (SV40-
TAg ) (46, 47). Cell lines generated through this method displayed
increased proliferation without tumorigenicity and remained pro-
liferative after multiple passages (46, 47). Additional retroviral
constructs targeting hTERT, TP53, and RB have all been shown
to be successful in the immortalization of primary HOSE cells
(48–52).
The recent development of small interfering RNAs (siRNAs)
has had an impact on ovarian cancer research as well. Primar-
ily used to silence genes through the RNA interference pathway
(RNAi), Yang et al. used siRNAs to immortalize OSE cells by tar-
geting p53 (53) and Rb (54), while others have used siRNAs to
explore the roles of PTTG (55), CD44 (56), and STAT3 (57). Cer-
tain investigators have even looked into siRNAs as a therapeutic
agent. Huang et al. showed that by using a lipidoid-mediated deliv-
ery of siRNAs targeting CLDN3, OVCAR-3 xenografts showed
reduced proliferation, metastasis, and tumor growth (58). The
benefits of siRNAs include ease of application and more rapid
results. However, specificity and cell toxicity have been a concern.
Fallopian tube models
The first fallopian tube epithelial cell (FTEC) culture system, devel-
oped for the purpose of studying the susceptibility of this epithe-
lium to neoplastic transformation, was described in 2010 (59).
Unlike traditional two-dimensional (2D) submerged cultures, this
“ex vivo” system allows FTECs to grow at the air-surface liquid
interface (Figure 3). This in-turn preserves the natural orienta-
tion, architecture, polarity, extracellular features, and biological
functions of in vivo FTECs, including the retention of ciliated
and secretory cells (59). Considering these advantages, this model
is ideal to explore the stresses of hormone exposure, ovulation,
and inflammatory response. In fact, Levanon et al. reported that
in response to DNA damage the FT-SECs display delayed DNA
repair kinetics compared to their ciliated cell neighbors (59). This
makes secretory cells more sensitive to DNA damage and could
explain why FT-SEC are susceptible to neoplastic transformation,
especially in the absence of key DNA repair proteins like BRCA1 or
BRCA2 (9). Despite the strengths of this model, it has two major
limitations. First, it is limited by the dependence on fresh primary
FT tissue. Second, the ex vivo cultures cannot be further propa-
gated in culture. While they remain viable for weeks, they are not
a renewable resource.
To alleviate the need for fresh tissue samples, and to create
a long term self-propagating cell population, Karst et al. utilized
fresh fallopian tube samples to create the first FT-SEC line (38). By
transducing hTERT and either SV40-TAg or an shRNA targeting
p53 and mutant CDK4R24C, FT-SECs were able to overcome senes-
cence and apoptosis (38). Further transduction of either HRAS
or an shRNA targeting the B56γ subunit of protein phosphatase
2A (PP2A-B56γ) and c-Myc resulted in an increase in prolifer-
ation, anchorage independent growth, and tumor formation in
implanted nude mice (38).
Jazaeri and colleagues reported similar results by adminis-
tering an oncogenic retroviral cocktail containing a myriad of
known oncogenes to primary FT-SEC (60). After a period pos-
itive selection due to proliferative advantages, the genetic profile
of transformed FT-SECs was determined. Increased c-Myc,HRAS,
hTERT, and SV40-TAg transgene expression and protein accumu-
lation was observed. Further experimentation showed that hTERT
and SV40-TAg expression was sufficient to overcome senescence
without tumor formation in nude mice (60). This confirmed the
findings of Karst et al. showing that FT-SECs are a possible source
for HG-SOC.
Further confirmation of these initial results was reported by
Shan et al. These investigators immortalized human FT-SECs by
overexpressing hTERT and SV40-TAg (61). However, when they
transduced the cells with oncogenic HRAS and implanted them
into nude mice, they observed tumor formation that resembled
poorly differentiated mucinous adenocarcinomas rather than HG-
SOC (61). This is consistent with recent reports showing that Type
I, low-grade tumors can emerge from the fallopian tube as well
(62, 63).
Recently, FTEC models have even stepped outside traditional
human cultures and expanded to baboons and pigs. A recent study
used baboon FTECs immortalized with SV40-TAg to study the
effect of ovulation on FTEC proliferation (64). Likewise, porcine
oviductal epithelial cells were used to optimize in vitro cell culture
conditions to maintain de novo FTEC morphological features, i.e.,
secretory and ciliated cells (65). These new methods could prove
useful as investigations into the FTEC continue to increase.
Conditionally reprogramed cells
An alternative to transgene immortalization is a newly developed
technique where epithelial cells are “reprogramed” into a stem cell
state through conditioned media. Schlegel et al. has been able to
show that primary human prostate, liver, lung, and breast epithe-
lial cells, when co-cultured with irradiated fibroblast feeder cells
in the presence of the rho-kinase inhibitor Y-27632, can undergo
unlimited expansion without senescence or apoptosis (66). This
increase in cell proliferation is accompanied by the up regulation
of stem cell markers and a decrease in Notch signaling (66). Even
more intriguing is that this phenotype is reversible. The removal of
Y-27632 and feeders results in the re-differentiation of cells accom-
panied with their natural polarity and orientation (66). Similarly,
Ince et al. showed that human mammary epithelial cells (HMECs)
are able to grow indefinitely in a serum-free, chemically defined
medium termed WIT (67). The optimization of these techniques
for either OSE cells or FT cells would be ideal and may eliminate
transgene manipulations and reduce potential off-target effects.
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Genome engineering
Despite its successes, certain drawbacks to retroviral transduction
and RNAi systems, like oncogenic effects, toxicity, and off-target
effects, have prompted investigators to develop targeted genome
editing systems. The application of custom DNA-binding pro-
teins, like transcription activator-like effector nuclease (TALENs)
and the clustered regularly interspaced short palindromic repeats
(CRISPR)/cas genome editing systems, have produced a flurry
of papers within the last few years. TALENs use a restriction
enzyme engineered to recognize specific DNA sequences through
the fusion of a TAL effector DNA-binding domain (68). Once
a gene is targeted, double strand breaks (DSBs) are introduced
and non-homologous end joining occurs (68). However, TALENs
are expensive to develop and suffer from off-target effects. The
CRISPR/cas system provides a cheaper alternative and works in
a similar manner. By utilizing endonucleases that use dual-RNAs
for site-specific DNA cleavage, investigators are able to exploit the
CRISPR/cas system for RNA-programmable genome editing (69).
This had been shown to be very effective and site-specific in con-
trolling gene expression and introducing genetic mutations (70).
Overall, despite its lack of validation and limited use with ovarian
cancer models, promising results should spark interest and new
avenues of investigation.
3D cultures
In addition to conventional 2D culture systems, three-dimensional
(3D) culture systems have become increasingly common. There
are five major types of 3D culture systems: scaffold free for spher-
oid growth, scaffolds, gels, bioreactors, and microchips. In these
settings, investigators concentrate on creating a more realistic envi-
ronment where cells of interest can interact with surrounding
tissues (71, 72). This seems relevant as studies show that differ-
ences in chemosensitivity, cell invasion, and protein expression
exist when epithelial ovarian cancer cells are cultured in either 2D
or 3D conditions (73–76). Difficulties associated with these mod-
els include cell removal, gelling variations, cost, and commercial
availability, although the further optimization of these techniques
should yield a host of useful tools.
ANIMAL MODELS OF OVARIAN CANCER
Genetically engineered mouse models
In contrast to cell culture platforms, which rely on an artificial
environment, genetically engineered mouse models are an effi-
cient alternative for genetic modification and tumor observations
in vivo. This is important, as questions regarding the identity of
cell lines and the selective pressures of cell culture systems con-
tinue to surface (77, 78). In addition, investigators have a broad
range of techniques to introduce genetic alterations in a temporal
or spatial-dependent manner. These methodologies employ trans-
genic elements, RNAi technologies, and viruses to create both loss
of function and gain of function traits within mice.
Limitations to these models include random integration of
transgenic elements, limited tissue specific promoters, and difficul-
ties achieving both spatial and temporal control simultaneously. In
addition to experimental difficulties, it is also challenging to accu-
rately mimic the human disease in rodents. For example, mice
require fewer genetic alterations for tumor induction compared
to humans (79–81). Furthermore, rodent tumors that are pro-
duced from defined genetic mutations do not always resemble
their human counterparts (79–81). The HRAS oncogene is a
prime example of this anomaly. Hamad et al. showed that the
mechanisms of Ras-induced transformation in mice differ when
compared to the mechanism of Ras-induced transformation in
humans (79). By systematically comparing the murine and mam-
malian transformation pathways investigators highlighted a crit-
ical disadvantage to non-human model systems; the genetic and
molecular disconnect between animal models and human disease.
However, the ability to validate gene function and test novel thera-
peutics in a relevant microenvironment, when paired with relevant
human studies, still makes these models especially useful (82).
Mouse OSE
Like other model systems, the initial ovarian cancer mouse models
focused on the OSE (5, 83–85). The first ovarian cancer trans-
genic mouse model was developed in 2002 (86). By inducing the
expression of the avian tumor virus receptor A (TVA) through the
control of the keratin-5 promoter, these investigators were able
to create a cell population within the mouse that was vulnerable
to avian retrovirus infection (86). However, the transient expres-
sion of keratin-5 required OSE viral infection to occur in vitro
with subsequent transplantation. Despite this drawback, infection
with different combinations of c-Myc, AKT, and KRas, produced
tumors in OSE cells harvested from TVAp53−/− mice and pro-
vided the first successful transgenic analysis of ovarian cancer in
mice (86).
A more specific promoter, the Mullerian Inhibitory Substance
Type II Receptor (MISIIR), was later identified and used by
Connolly et al. to drive gynecological tissue specific transgene
expression of SV40-TAg in mice resulting in the formation of
ovarian carcinoma in 50% of the transgenic founders (87). How-
ever, aggressive tumor formation prohibited the study of early
stage tumors and prevented reproduction. Additional studies uti-
lizing the MISIIR promoter explored the oncogenic properties
of PTTG and PIK3CA, however both had difficulties producing
tumors (88, 89).
Rather than identify a specific promoter, some investigators
have employed the Cre-loxP method to deliver specific genetic
alterations (90). Administration of the Cre recombinase can be
achieved either through injection of a viral vector (AdCre) or by
crossing with a mouse generated to express the protein. This model
is a clever way to circumvent problems inherent to typical trans-
genic models and has been used study TP53 and Rb (91), KRas
and PTEN (92), PTEN and APC (93), and BRCA1 (94) within the
context of ovarian cancer.
Most recently, Flesken-Nikitin and colleagues applied the
AdCre system to perturb p53 and Rb in a stem cell niche in the
transitional zone of the bursal cavity of mice. With p53 and Rb
inactivated, these stem cells in the hilum region showed the earliest
signs of transformation (95). However, perhaps the more inter-
esting aspect of this study was the reporter mouse developed to
characterize the fate of the hilum stem cells. A stem cell marker
(LRG5), specific to the hilum region, was used to drive specific
expression of CreERT2. In turn, subsequent tamoxifen (TAM)
administration created a traceable knocked-in fluorescent probe.
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Results indicated that hilum cells do have the potential to repop-
ulate the ovarian surface and suggest that stem cell niches could
contribute to HG-SOC (95). Whether the hilar cells are OSE cells,
or a different cell type altogether, remains to be seen. It is also
worth noting that, since there is no bursa surrounding the human
ovaries, it is not clear whether there is an equivalent structure or
cell type in humans.
Overall, the mouse models developed thus far have focused on
the OSE and some have exhibited difficulties with tumorigenicity,
female reproduction, anatomical anomalies, and transient expres-
sion. Likewise, while these models have offered insight into genes
that are important to transformation, they have not provided
insight into HG-SOC preneoplastic lesions as such lesions have
yet to be identified in the ovary. We anticipate that animal models
that target the fallopian tube secretory cell will provide additional
insights.
Mouse fallopian tube
The first mouse model targeting the extra-ovarian Mullerian
epithelium was developed by Miyoshi et al. By exploiting the pro-
moter of the murine oviduct-specific glycoprotein, Miyoshi was
able to drive expression of the SV40-TAg in the oviduct, uterus,
vagina, and ovary. Except for the ovary, subsequent tumor for-
mation throughout the female reproductive tract was observed
(96). Tumor formation was reduced in ovariectomized mice, but
when estradiol was injected subcutaneously a dramatic increase in
hyperplasia of the extra-ovarian Mullerian epithelia was observed
(96). This suggests that ovarian cancer could originate outside the
ovary, and that these preneoplastic lesions are highly reliant on
hormone regulation pathways involving the ovary.
More recently, Kim et al. disabled DICER and PTEN using the
anti-Mullerian hormone receptor type 2-directed Cre (Amhr2-
Cre) (97). HG-SOC with aggressive metastasis was observed in
these mice resulting in 100% death. In addition, the fallopian tube
displayed the earliest lesions and cancer was prevented when the
fallopian tube was removed at an early age (97). However, the first
signs of increased proliferation within the fallopian tube appear to
reside in the stromal compartment, counterintuitive to the epithe-
lial properties presented in the advanced HG-SOC. Equally vexing
was the low p53 expression in mouse tumors, a protein known
to be mutated and highly expressed in almost 100% of human
tumors (7).
Other animal models
An alternative to the mouse model, which has dominated the field
since its initial use, is the domestic laying hen. The hen is the
only animal identified to spontaneously develop HG-SOC that
is histologically and morphologically similar to human HG-SOC
(98). Likewise, because ovarian cancer of the hen presents so many
similarities to human ovarian cancer, there are many opportuni-
ties to explore early preneoplastic lesions, chemopreventive trials,
and perform genomic analyses (99). Disadvantages include a lack
of reagents and genetic manipulation technologies that target the
hen, as well as anatomical discrepancies (99).
CONCLUSION
Our understanding of ovarian cancer has dramatically changed
in the last 10 years. In our search for a cell of origin, our evolv-
ing knowledge about the pathogenesis of the disease has led us to
sites neighboring the ovary. At the same time, we now appreci-
ate that this is a heterogeneous disease with a complex genomic
landscape. In particular, HG-SOCs are marked by surprisingly few
recurrent somatic mutations. Instead, this tumor exhibits a com-
plex genome marked by copy number alterations so widespread
that few other cancer types mirror its complexity. The challenge
now is to elucidate the key alterations related to tumorigenesis,
tumor viability, and chemotherapy resistance. In order to achieve
this goal, experimental model systems must take center stage and
continue to evolve to meet the demanding needs of the scientific
community.
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